Covid-19 treatment hopes as GlaxoSmithKline's antibody drug moves onto phase 3 trial

Brentford-based GlaxoSmithKline (GSK) said its treatment - known as Vir-7831 - could be rolled out by 2021 if its proven to be effective and safe.